Nektar Therapeutics Bolsters Cash Position with $351M Offering, Advances Rezpegaldesleukin into Phase 3
Event summary
- Nektar Therapeutics reported $731.6M in cash and investments as of March 31, 2026, excluding $351M from a recent secondary offering.
- Revenue for Q1 2026 was $10.9M, with R&D expenses increasing to $35.7M due to Phase 3 preparations for rezpegaldesleukin in atopic dermatitis.
- Net loss for Q1 2026 narrowed to $44.9M from $50.9M in Q1 2025, reflecting reduced G&A expenses.
- Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis set to initiate by July 2026.
- End-of-Phase 2 meeting with FDA for alopecia areata program scheduled for Q2 2026.
The big picture
Nektar Therapeutics is positioning itself for a pivotal year in 2026, with a strengthened balance sheet and key clinical milestones on the horizon. The company's focus on autoimmune diseases aligns with the growing demand for targeted immunotherapies, but its success will hinge on the regulatory and commercial viability of rezpegaldesleukin. The recent funding rounds suggest strong investor confidence, but the biotech's ability to translate clinical data into marketable products remains the ultimate test.
What we're watching
- Clinical Milestones
- The initiation of the Phase 3 ZENITH-AD program and the End-of-Phase 2 meeting with the FDA will be critical in determining the regulatory path for rezpegaldesleukin.
- Financial Sustainability
- With over $1B in cash and investments post-offering, Nektar's ability to sustain its R&D-heavy strategy will depend on the success of its lead candidates.
- Pipeline Progress
- The pace at which Nektar can advance its preclinical programs, such as NKTR-0165, will influence its long-term growth prospects beyond rezpegaldesleukin.
Related topics